{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,23]],"date-time":"2026-08-23T17:19:34Z","timestamp":1787505574485,"version":"build-2736575974"},"reference-count":15,"publisher":"Oxford University Press (OUP)","issue":"5","license":[{"start":{"date-parts":[[2024,1,23]],"date-time":"2024-01-23T00:00:00Z","timestamp":1705968000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/academic.oup.com\/pages\/standard-publication-reuse-rights"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2024,5,31]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:p>In this work, an eco-friendly simple, precise reverse phase high-performance liquid chromatography (HPLC) method has been developed and validated for Favipiravir in bulk and tablet dosage form followed by its force degradation study. The proposed method was validated to obtain official requirements including stability, accuracy, precision, linearity, robustness and selectivity as per International Council for Harmonisation of Technical Requirements for Pharmaceuticals for Human Use (ICH) Guidelines. The estimation was developed on C (18) column reversed-phase using the mobile phase composition as methanol:water (10:90\u00a0v\/v). The flow rate was set as 1\u00a0ml\/min, and the maximum absorption was observed at 323\u00a0nm using Shimadzu Photo Diode Array detector. The Favipiravir, drug showed a precise and good linearity at the concentration ranges of 10\u201350\u00a0\u03bcg\/mL. The Revearse Phase High Perforance Liquid Chromatography assay showed the highest purity ranging from 99.90 to 100.02% for Favipiravir, tablet dosage form, and 100.15% was the mean percentage purity. The percent recovery was found within the acceptance limit of (98.6\u2013100.0%). Intra- and inter-day precision studies of the method were less than the maximum allowable limit percentage of relative standard deviation\u2009\u2264\u20092.0. The Favipiravir retention time was found to be 5.00\u00a0min. To examine the stability of the drug, various forced degradation studies were conducted on Favipiravir Active Pharmaceutical Ingredient. The developed method was validated according to the ICH guidelines. A very quick, cost-effective, precise and accurate HPLC method for the determination of Favipiravir has been developed and validated in compliance with ICH guidance Q2.<\/jats:p>","DOI":"10.1093\/chromsci\/bmad093","type":"journal-article","created":{"date-parts":[[2023,12,26]],"date-time":"2023-12-26T11:59:13Z","timestamp":1703591953000},"page":"432-438","source":"Crossref","is-referenced-by-count":10,"title":["An Eco-Friendly RP-HPLC Method Development and Validation for Quantification of Favipiravir in Bulk and Tablet Dosage Form Followed by Forced Degradation Study"],"prefix":"10.1093","volume":"62","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-8428-4324","authenticated-orcid":false,"given":"Monika B","family":"Sangani","sequence":"first","affiliation":[{"name":"Department of Pharmaceutical Sciences, Saurashtra University , Rajkot-360005, Gujarat , India"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nirav","family":"Patel","sequence":"additional","affiliation":[{"name":"Pharmaceutical and Process Technology, Patheon Inc. , -ON, L5N, 7K9 , Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"286","published-online":{"date-parts":[[2024,1,23]]},"reference":[{"key":"2024060202553410100_ref1","volume-title":"Favipiravir: Uses, Interactions, Mechanism of Action","author":"Go.drugbank.com","year":"2022"},{"issue":"4","key":"2024060202553410100_ref2","doi-asserted-by":"crossref","first-page":"370","DOI":"10.1016\/j.mjafi.2020.08.004","article-title":"Favipiravir: A new and emerging antiviral option in COVID-19","volume":"76","author":"Agrawal","year":"2020","journal-title":"Medical Journal, Armed Forces India"},{"key":"2024060202553410100_ref3","doi-asserted-by":"crossref","first-page":"501","DOI":"10.1016\/j.ijid.2020.10.069","article-title":"Role of favipiravir in the treatment of COVID-19","volume":"102","author":"Joshi","year":"2020","journal-title":"International Journal of Infectious Disease"},{"key":"2024060202553410100_ref4","volume-title":"A kind of Favipiravir has the HPLC assay method of related substance","author":"Shandong Academy of Pharmaceutical Sciences, China patent (CN104914185B)"},{"key":"2024060202553410100_ref5","author":"Shandong Academy of Pharmaceutical Sciences, China patent (CN104914185A); HPLC method for measuring related substances in Favipiravir. 16.09.2015."},{"issue":"3","key":"2024060202553410100_ref6","doi-asserted-by":"crossref","first-page":"209","DOI":"10.1556\/1326.2020.00828","article-title":"HPLC-UV method for quantification of Favipiravir in pharmaceutical formulations","volume":"33","author":"Buldukibrahim","year":"2021","journal-title":"Acta Chromatographica"},{"key":"2024060202553410100_ref7","doi-asserted-by":"crossref","first-page":"497","DOI":"10.1016\/j.trac.2008.05.003","article-title":"Green analytical chemistry","volume":"27","author":"Armenta","year":"2008","journal-title":"Trends in Analytical Chemistry"},{"key":"2024060202553410100_ref8","volume-title":"Proceedings of the International Conference on Harmonization of Technical Requirements for Registration of Pharmaceuticals for Human Use","year":"2005"},{"key":"2024060202553410100_ref9","volume-title":"Reviewer Guidance, Validation of Chromatographic Methods","author":"United States Food and Drug Administration.","year":"2022"},{"issue":"6","key":"2024060202553410100_ref10","doi-asserted-by":"crossref","first-page":"1011","DOI":"10.1016\/S0731-7085(02)00047-X","article-title":"Development of validated stability-indicating assay methods - critical review","volume":"28","author":"Bakshi","year":"2002","journal-title":"Journal of Pharmaceutical and Biomedical Analysis"},{"issue":"2","key":"2024060202553410100_ref11","doi-asserted-by":"crossref","first-page":"302","DOI":"10.1016\/j.ijpharm.2006.12.011","article-title":"In vitro behavior of a phosphate ester prodrug of amprenavir in human intestinal fluids and in the Caco-2 system: Illustration of intraluminal supersaturation","volume":"336","author":"Brouwers","year":"2007","journal-title":"International Journal of Pharmaceutics"},{"key":"2024060202553410100_ref12","article-title":"Stability indicative and cost effective analytical method development and validation of Favipiravir and peramivir in bulk and pharmaceutical dosage form by using RP-HPLC","volume":"13","author":"Lingabathula","year":"2021","journal-title":"International journal of applied pharmaceutics"},{"key":"2024060202553410100_ref13","doi-asserted-by":"crossref","DOI":"10.1016\/j.microc.2021.106917","article-title":"A novel stability-indicating HPLC-DAD method for determination of Favipiravir, a potential antiviral drug for COVID-19 treatment; application to degradation kinetic studies and in-vitro dissolution profiling","volume":"172","author":"Marzouk","year":"2022","journal-title":"Microchemical Journal"},{"key":"2024060202553410100_ref14","volume-title":"The Health Ministers of the United Kingdom, British Pharmacopoeia","year":"2001"},{"key":"2024060202553410100_ref15","doi-asserted-by":"crossref","first-page":"204","DOI":"10.1016\/j.talanta.2018.01.013","article-title":"A new tool for the evaluation of the analytical procedure: Green analytical procedure index","volume":"181","author":"P\u0142otka-Wasylka","year":"2018","journal-title":"Talanta"}],"container-title":["Journal of Chromatographic Science"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/academic.oup.com\/chromsci\/article-pdf\/62\/5\/432\/58033500\/bmad093.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/chromsci\/article-pdf\/62\/5\/432\/58033500\/bmad093.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,6,1]],"date-time":"2024-06-01T22:56:03Z","timestamp":1717282563000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/chromsci\/article\/62\/5\/432\/7585643"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,1,23]]},"references-count":15,"journal-issue":{"issue":"5","published-online":{"date-parts":[[2024,1,23]]},"published-print":{"date-parts":[[2024,5,31]]}},"URL":"https:\/\/doi.org\/10.1093\/chromsci\/bmad093","relation":{},"ISSN":["0021-9665","1945-239X"],"issn-type":[{"value":"0021-9665","type":"print"},{"value":"1945-239X","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2024,5]]},"published":{"date-parts":[[2024,1,23]]}}}